Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Желудочковые аритмии при хронической сердечной недостаточности: особенности лечения и возможности улучшения прогноза
________________________________________________
Bunin Y.A., Zolozova E.А. Ventricular arrhythmias in chronic heart failure: features of treatment and the possibility of improving the prognosis. Consilium Medicum. 2019; 21 (5): 57–61. DOI: 10.26442/20751753.2019.5.190419
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Ключевые слова: хроническая сердечная недостаточность, желудочковая тахикардия, фибрилляция желудочков, антиаритмические препараты, имплантируемые кардиовертеры-дефибрилляторы, кардиальная ресинхронизирующая терапия, радиочастотная катетерная аблация.
________________________________________________
Key words: chronic heart failure, ventricular tachycardia, ventricular fibrillation, antiarrhythmic drugs, implantable cardioverter-defibrillators, cardiac resynchronization therapy, radiofrequency catheter ablation.
2. Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction. Eur Heart J 2012; 33: 1750–7.
3. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J 2012; 33: 1787–847.
4. Maggioni AP, Zuanetti G, Franzosi MG et al. Prevalence and prognostic significance of ventricular arrhythmias after acute myocardial infarction in the fibrinolytic era. GISSI-2 results. Circulation 1993; 87: 312–22.
5. Deyell MW, Park KM, Han Y et al. Predictors of recovery of left ventricular dysfunction after ablation of frequent ventricular premature depolarizations. Heart Rhythm 2012; 9: 1465–72.
6. 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J 2015. DOI: 10.1093eurheartj/ehv316
7. Desai AS, Mc Murray JJ, Packer M et al. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J 2015; 36: 1990–7.
8. Kotecha D, Holmes J, Krum H et al. Beta-blockers in heart failure collaborative group. Efficacy of beta-blockers in patients with heart failure plus atrial fibrillation. Lancet 2014; 384: 2235–43.
9. Bapoje SR, Bahia A, Hokanson JE et al. Effect of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with left ventricular systolic dysfunction: a meta-analysis of randomized controlled trials. Circ Heart Fail 2013; 6: 166–73.
10. Piccini JP, Berger JS, O’Connor CM. Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials. Eur Heart J 2009; 30 (10): 1245–53.
11. Boutitie F, Boissel J-P, Connolly SJ. Amiodarone interaction with beta-blockers: analysis of the merged EMIAT and CAMIAT databases. The EMIAT and CAMIAT investigators. Circulation 1999; 99 (17): 2268–75.
12. Bardy GH, Lee KL, Mark DB et al. Amiodarone or implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352 (2): 225–37.
13. Velazquez EJ, Lee KL, Deja MA et al. STICH investigators. Coronary-artery bypass surgery in patients with ventricular dysfunction. N Engl J Med 2011; 364: 1607–16.
14. Carson P, Wertheimer J, Miller A et al. The STICH trial: mode-of-death results. JACC Heart Fail 2013; 1: 400–8.
15. NanthaKumar K, Epstein AE, Kay GN et al. Prophylactic implantable cardioverter-defibrillator therapy in patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2004; 44 (11): 2166–72.
16. Kadish A, Dyer A, Daubert JP et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004; 350: 2151–8.
17. Desai AS, Fang JC, Maisel WH, Baughman KL. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials. JAMA 2004; 292: 2874–9.
18. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. JACC DOI: 10.1016/J.Jacc.2017.10.054
19. Bristow MR, Saxon LA, Boehmer J et al. Comparison of medical therapy, pacing and defibrillator in heart failure (COMPANION) investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350: 2140–50.
20. Cleland JG, Daubert JC, Erdmann E. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005; 352: 1539–49.
21. Gasparini M, Leclercq C, Lunati M et al. Cardiac resynchronization therapy in patients with atrial fibrillation: the CERTIFY study. JACC Heart Fail 2013; 1: 500–7.
22. Connolly SJ, Hallstrom AP, Cappato R et al. Meta-analysis of the implantable cardioverter-defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Eur Heart J 2000; 21: 2071–8.
23. Connoly SJ, Dorian P, Roberts RS et al. Comparison of beta-blockers, amiodarone plusbeta-blockers or sotalol for prevention of shocks from implantable cardioverter-defibrillators. The OPTIC study. JAMA 2006; 295: 165–71.
24. Tanner H, Hindricks G, Volkmer M et al. Catheter ablation of recurrent scar-related ventricular tachycardia using electroanatomical mapping and irrigated ablation technology: results of the prospective multicenter Euro-VT-study. J Cardiovasc Electrophysiol 2010; 21: 47–53.
________________________________________________
1. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. DOI: 10.1093/eurheart/ehw128
2. Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction. Eur Heart J 2012; 33: 1750–7.
3. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J 2012; 33: 1787–847.
4. Maggioni AP, Zuanetti G, Franzosi MG et al. Prevalence and prognostic significance of ventricular arrhythmias after acute myocardial infarction in the fibrinolytic era. GISSI-2 results. Circulation 1993; 87: 312–22.
5. Deyell MW, Park KM, Han Y et al. Predictors of recovery of left ventricular dysfunction after ablation of frequent ventricular premature depolarizations. Heart Rhythm 2012; 9: 1465–72.
6. 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J 2015. DOI: 10.1093eurheartj/ehv316
7. Desai AS, Mc Murray JJ, Packer M et al. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J 2015; 36: 1990–7.
8. Kotecha D, Holmes J, Krum H et al. Beta-blockers in heart failure collaborative group. Efficacy of beta-blockers in patients with heart failure plus atrial fibrillation. Lancet 2014; 384: 2235–43.
9. Bapoje SR, Bahia A, Hokanson JE et al. Effect of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with left ventricular systolic dysfunction: a meta-analysis of randomized controlled trials. Circ Heart Fail 2013; 6: 166–73.
10. Piccini JP, Berger JS, O’Connor CM. Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials. Eur Heart J 2009; 30 (10): 1245–53.
11. Boutitie F, Boissel J-P, Connolly SJ. Amiodarone interaction with beta-blockers: analysis of the merged EMIAT and CAMIAT databases. The EMIAT and CAMIAT investigators. Circulation 1999; 99 (17): 2268–75.
12. Bardy GH, Lee KL, Mark DB et al. Amiodarone or implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352 (2): 225–37.
13. Velazquez EJ, Lee KL, Deja MA et al. STICH investigators. Coronary-artery bypass surgery in patients with ventricular dysfunction. N Engl J Med 2011; 364: 1607–16.
14. Carson P, Wertheimer J, Miller A et al. The STICH trial: mode-of-death results. JACC Heart Fail 2013; 1: 400–8.
15. NanthaKumar K, Epstein AE, Kay GN et al. Prophylactic implantable cardioverter-defibrillator therapy in patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2004; 44 (11): 2166–72.
16. Kadish A, Dyer A, Daubert JP et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004; 350: 2151–8.
17. Desai AS, Fang JC, Maisel WH, Baughman KL. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials. JAMA 2004; 292: 2874–9.
18. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. JACC DOI: 10.1016/J.Jacc.2017.10.054
19. Bristow MR, Saxon LA, Boehmer J et al. Comparison of medical therapy, pacing and defibrillator in heart failure (COMPANION) investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350: 2140–50.
20. Cleland JG, Daubert JC, Erdmann E. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005; 352: 1539–49.
21. Gasparini M, Leclercq C, Lunati M et al. Cardiac resynchronization therapy in patients with atrial fibrillation: the CERTIFY study. JACC Heart Fail 2013; 1: 500–7.
22. Connolly SJ, Hallstrom AP, Cappato R et al. Meta-analysis of the implantable cardioverter-defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Eur Heart J 2000; 21: 2071–8.
23. Connoly SJ, Dorian P, Roberts RS et al. Comparison of beta-blockers, amiodarone plusbeta-blockers or sotalol for prevention of shocks from implantable cardioverter-defibrillators. The OPTIC study. JAMA 2006; 295: 165–71.
24. Tanner H, Hindricks G, Volkmer M et al. Catheter ablation of recurrent scar-related ventricular tachycardia using electroanatomical mapping and irrigated ablation technology: results of the prospective multicenter Euro-VT-study. J Cardiovasc Electrophysiol 2010; 21: 47–53.
ФГБОУ ДПО «Российская медицинская академия непрерывного последипломного образования» Минздрава России, Москва, Россия
*ezolozova@mail.ru
________________________________________________
Russian Medical Academy of Continuous Professional Education, Moscow, Russia
*ezolozova@mail.ru